We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 233

Court of Appeal upholds decision to deny amendments to statement of defence in Section 8 proceeding Sanofi-Aventis Canada Inc. v. Teva Canada Limited, 2014 FCA 65
  • Borden Ladner Gervais LLP
  • Canada
  • March 24 2014

This appeal was heard in the context of an action commenced by Teva Canada Limited (“Teva”) seeking compensation from Sanofi-Aventis Canada Inc. and


Final injunction permits existing patients to continue to receive infringing medicine
  • Borden Ladner Gervais LLP
  • Canada
  • June 10 2014

This decision relates to the crafting of a final injunction for the sale of STELARA following a finding of infringement. In an earlier trial decision


Teva's allegation for section 8 damages not struck on appeal
  • Borden Ladner Gervais LLP
  • Canada
  • October 28 2013

Pfizer appealed a decision refusing to strike Teva’s Statement of Claim to the Federal Court, but the appeal was dismissed because a de novo review


Order of prohibition granted in respect of one of two asserted patents
  • Borden Ladner Gervais LLP
  • Canada
  • October 28 2013

Two patents were under consideration by the Court in this application brought pursuant to the Patented Medicines (Notice of Compliance) Regulations


Court bifurcates determination of Start Date for section 8 action
  • Borden Ladner Gervais LLP
  • Canada
  • May 30 2014

This is an action commenced pursuant to section 8 of the Patented Medicines (Notice of Compliance) Regulations. Pfizer counterclaimed against Apotex


Supreme Court denies Apotex leave to appeal; prohibition order stands
  • Borden Ladner Gervais LLP
  • Canada
  • April 30 2014

The Supreme Court of Canada (SCC) denied Apotex leave to Appeal the decision of the Federal Court of Appeal (FCA) in a s. 8 case (decision here


Oder of prohibition issues no promise to treatment in humans or reduced side effects was found
  • Borden Ladner Gervais LLP
  • Canada
  • April 30 2014

Pfizer’s Canadian Patent No. 2,177,576 for Celebrex has withstood Apotex’s allegations and was found to be valid; therefore the Minister is


Court dismisses NOC proceeding for mootness when NOA withdrawn
  • Borden Ladner Gervais LLP
  • Canada
  • January 30 2013

Lilly brought an application for prohibition pursuant to the Patented Medicines (Notice of Compliance) Regulations. Subsequently, Teva established to


Teva Canada Innovation v. Attorney General of Canada
  • Borden Ladner Gervais LLP
  • Canada
  • May 8 2013

The Patented Medicine Prices Review Board (the PMPRB) ordered Teva to pay the Crown approximately $2.4 million for selling its product at an


Order of prohibition overturned on appeal
  • Borden Ladner Gervais LLP
  • Canada
  • June 16 2014

The issue to be determined by the Court of Appeal related to whether the allegation of lack of utility was justified. The Court of Appeal began by